L-arginine-induced vasodilation in healthy humans: Pharmacokinetic-pharmacodynamic relationship

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 489-497

  Bode Böger, Stefanie M ^a   Böger, Rainer H ^a   Galland, Andrea ^a   Tsikas, Dimitrios ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Endothelium; Impedance cardiography; Nitric oxide; Non compartmental analysis; Peripheral resistance

Indexed keywords

ARGININE; CYCLIC GMP; NITRATE; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; IMPEDANCE CARDIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; ARGININE; BLOOD PRESSURE; CARDIAC OUTPUT; CYCLIC GMP; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NITRATES; NITRIC OXIDE; VASODILATION;

EID: 0031731634     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00803.x     Document Type: Article

References (55)

1. Moncada S, Higgs EA. The L-arginine - nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
2. Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131.
3. Wennmalm A, Benthin G, Edlund A, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Ciculation 1993; 73: 1121-1127.
4. 3 excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin Exp Pharmacol Physiol 1996; 23: 11-15.
5. Tolins JP, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990; 27: H655-H662.
6. Bode-Böger SM, Böger RH, Creutzig A, et al. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 1994; 87: 303-310.
7. Bode-Böger SM, Böger RH, Alfke H, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996; 93: 85-90.
8. Kanno K, Hirata Y, Emori T, et al. L-arginine infusion induces hypotension and diuresis/natriuresis concomitant with increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol 1992; 19: 619-625.
9. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesteroleimc humans. J Clin Invest 1992; 90: 1248-1253.
10. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
11. 15O-water PET study. Clin Sci 1997; 93: 159-165.
12. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-1994.
13. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995; 26: 1054-1061.
14. Adams MR, Jessup W, Hailstones D, Celermajer DS. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997; 95: 662-668.
15. Merimee TJ, Lillicrap DA, Rabinowitz D. Effect of arginine on serum-levels of human growth hormone. Lancet 1965; ii: 668-670.
16. Visck WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986; 116: 36-46.
17. Matera M, Castana R, Insirello L, Leonardi G. Pharmacokinetic study of the relative bioavailability and bioeqinvalence atter oral intensive or repeated short term treatment with two polyamino acid formulations. Int J Clin Pharm Res 1993; 13: 93-105.
18. 15N-labelled analogs. J Chromatogr B 1994; 661: 185-191.
19. Tsikas D, Gutzki FM, Rossa S, et al. Measurement of nitrite and nitrate in biological fluids by gas chromatography-mass spectrometry and by the Griess assay: Problems with the Griess assay - solutions by gas chromatography-mass spectrometry. Anal Biochem 1997; 244: 208-220.
20. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
21. Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RM. Development and evaluation of an impedance cardiac output system. Aerospace Med 1966; 37: 1208-1212.
22. Belardinelli R, Ciampani N, Costanini C, Blandini A, Purcaro A. Comparison of impedance cardiography with thermodilution and direct Fick methods for noninvasive measurement of stroke volume and cardiac output during incremental exercise in patients with ischemic cardiomyopathy. Am J Cardiol 1996; 77: 1293-1301.
23. Breithaupt K, Erb K, Neumann B, Wolf GK, Belz GG. Comparison of four noninvasive techniques to measure stroke volume; dual beam Doppler echoaortography, electrical impedance cardiography, mechanosphygmography, and M-mode echocardiography on the left ventricle. Am J Noninvas Cardiol 1990; 4: 203-209.
24. Heinzel G, Woloszczak R, Thomann P. TOPFIT 2.0 Pharmacokinetic and Pharmacodynamik Data Analysis System for the PC. Gustav Fischer, Stuttgart, Jena, New York 1993.
25. Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmac Ther 1982; 16: 143-166.
26. Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmakodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86-93.
27. Giugliano D, Marfella R, Verrazzo G, et al. The vascular effects of L-arginine in humans. The role of endogenous insulin. J Clin Invest 1997; 99: 433-438.
28. Rector TS, Blanck AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135-2141.
29. Mehta S, Stewart DJ, Levy RD. The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 1996; 109: 1550-1555.
30. Cooke JP, Rossitch E, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663-1671.
31. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH. The nature of the endothelium-derived vascular relaxant factor. Nature 1984; 308: 645-647.
32. Pollock JS, Förstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-10484.
33. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
34. G dimethylarginine by human endothelial cells. Endothelium 1993; 1: 137-140.
35. Böger RH, SM Bode-Böger, PS Tsao, PS Lin, JR Chan, JP Cooke. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherosclerotic effects in cultured human endothelial cells [Abstract]. Circulation 1997; 96 (Suppl.): I-1588.
36. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
37. + by arginine analogs that inhibit nitric oxide synthase. Biochim Biophys Acta 1997; 1324: 133-141.
38. Krieg RJ, Santos F, Chan JCM. Growth hormone, insulin-like growth factor and the kidney. Kidney Int 1995; 48: 321-336.
39. G-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-1. J Clin Invest 1996; 97: 1319-1328.
40. Böger RH, Skamira C, Bode-Böger SM, Brabant G, von zur Mühlen A, Frölich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996, 98: 2706-2713.
41. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
42. Calver A, Collier J, Vallance P. Dilator actions of arginine in human peripheral vasculature. Clin Sci 1991; 81: 695-700.
43. Bode-Böger SM, Böger RH, Schröder EP, Frölich JC. Exercise increases systemic NO production in men. J Cardiovasc Risk 1994; 1: 173-178.
44. Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake by the splanchnic region in adult humans. Am J Physiol 1993; 265: E532-F539.
45. Noeh FM, Wenzel A, Harris N, et al. The effects of arginine administration on the levels of arginine, other amino acids and related compounds in the plasma, heart, aorta, vena cava, bronchi and pancreas of the rat. Life Sci 1996; 58: 131-138.
46. White MF, Christensen HN. Cationic amino acid transport into cultured animal cells. II. Transport system barely perceptible in ordinary hepatocytes, but active in hepatoma cell lines. J Biol Chem 1982; 258: 8028-8038.
47. Felig P, Wahren J. Amino acid metabolism in exercising num. J Clin Invest 1971; 50: 2703-2714.
48. Blanchier F, Darcy-Vrillon B, Sener A, Duéc PH, Malaisse WJ. Arginine metabolism in rat enerocytes. Biochim Biophys. Acta 1991; 1092: 304-310.
49. Windmueller HG, Spaeth AE. Source and fate of citrulline. Am J Physiol 1981; 241: E473-E480.
50. Brusilow SW, Horwich AL. Urea cycle enzymes. In: The metabolic basis of inherited disease (6th ed.) Eds Scriver CR, Beaduet AL, Sly WS, Valle D. St. Louis: McGraw-Hill, 1989, pp. 629-663.
51. Lortie MJ, Novotny WL, Peterson OW, et al. Agmatine, a bioactive metabolite of arginine. J Clin Invest 1996; 97: 413-420.
52. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
53. Castillo L, DeRojas TC, Chapman TE, et al. Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man. Proc Natl Acad Sci USA 1993; 90: 193-197.
54. Rhodes PM, Leone AM, Francis PL, Struthers AD, Moncada S. The L-arginine : nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995; 209: 590-596.
55. Leaf CD, Wishnok JS, Tannenbaum SR. L-arginine is a precursor for nitrate biosynthesis in humans. Biochem Biophys Res Commun 1989; 163: 1032-1037.